RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Vivo Capital
V

Vivo Capital portfolio

Vivo Capital has 9 portfolio companies on record at Recent Funding, with 3 investments in the last 12 months.

Website: vivocapital.com.
Type: Venture capital.
Portfolio on Recent Funding: 9.
Deals, last 12 months: 3.
Rounds led: 2 of 9.
Capital in their rounds: $330M.
Latest deal: Langlai Technology · Nov 14, 2026.
About this page

It is a venture capital firm based in Palo Alto, US, founded in 1996. It led 2 of the 9 rounds it joined. Its most recent investment on record is Langlai Technology's Series B+ round in November 2026, alongside PICC Capital Investment Management, Qianhai Ark Capital, Changjiang Capital and 2 others. By category, its portfolio leans toward Health and bio (9) and Logistics and mobility (1). It has co-invested with Sixty Degree Capital, Pictet Alternative Advisors and Lilly Asia Ventures, most often Sixty Degree Capital (2 rounds).

About Vivo Capital

Firm type: Venture capital.
Headquarters: Palo Alto, US.
Founded: 1996.
Stages: Seed, Series A, Series B, Series C, Growth, Late Stage.
Sectors: Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Check size: $10M to $50M.
Leads rounds: Yes.
Portfolio companies: 95.
Exits: 2.
Rounds led: 7.

Fund returns

FundVintageSizeNet IRRTVPIDPIAs of
Vivo Capital IX2019—18.8%1.73x0.70xJun 30, 2025
Vivo Opportunity Fund, LP2018——1.84x1.84xMar 31, 2025
Vivo Capital Fund VIII, L.P.2015—14.9%1.96x1.51xJun 30, 2025
Vivo Capital Surplus Fund VIII, L.P.2015—15.9%2.01x1.55xJun 30, 2025

Funds raised

FundFund #SizeAnnounced
VVivo CapitalIII$740M
Venture Capital Journal

What Vivo Capital invests in

Vivo Capital recent investments

How Vivo Capital invests

StageDealsCapital in rounds
Series B+ 7 78%$278M
Series A 1 11%$52M
Seed 1 11%undisclosed
YearDealsCapital in rounds
2021 2 22%$73M
2022 3 33%$154M
2024 1 11%undisclosed
2026 3 33%$103M

Vivo Capital portfolio companies

CompanyRound with Vivo CapitalTotal raisedLatest raise
LLanglai Technology
Health and bio
Series B+undisclosedNov 14, 2026
Series B+
SSeran Bioscience
Health and bio
Series B+undisclosedSep 29, 2026
Series B+
KKinaset Therapeutics
Health and bio
Series B+ · $103M$143MJan 9, 2026
Series B+
335Pharma
Health and bio
Series B+undisclosedNov 26, 2024
Series B+
PPulmocide
Health and bio
Series B+ · $52M · lead$174.4MDec 6, 2022
Series B+
RRgenta Therapeutics
Health and bio
Series A · $52M$52MNov 3, 2026
Series B+
IInspirna
Health and bio
Series B+ · $50M · lead$50MJul 11, 2022
Series B+
IImmune-Onc Therapeutics
Health and bio
Series B+ · $73M$211MJan 5, 2023
Series B+
OOricell Therapeutics
Health and bio
backer$235MApr 10, 2026
round

Most frequent co-investors

Acquisitions

Acquired companyAnnounced
DDutscher · markets.financialcontent

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Net returns as reported by the public-pension and foundation LPs invested in each fund.

Firm profile and fund returns: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Venture funds Vivo Capital raised, from the list of new VC funds compiled by Shai Goldman (Brex). Each size links to the article that states it, or to that list where no article was found. All new funds: new VC funds.

Share is of the 9 rounds on Recent Funding that name Vivo Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Vivo Capital, which is a subset of its real portfolio. API: /api/v1/investors/vivo-capital (get a free API key). More: the most active VC firms and new venture capital funds.

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy